In the rapidly evolving field of gene editing, CRISPR technology has emerged as a revolutionary tool, enabling precise and efficient modifications to the genome. While the CRISPR-Cas9 system has garnered widespread attention for its ability to create double-strand breaks at specific DNA sites, the development of newer CRISPR-based tools, such as base editors (BEs) and prime editors (PEs), has significantly expanded the scope of genetic engineering.
Read more...
BE allows for the conversion of single nucleotide bases without creating double-strand breaks, making it a powerful tool for correcting point mutations, which account for a significant proportion of genetic diseases. PE, on the other hand, offers even greater versatility by enabling precise insertions, deletions and all 12 possible base-to-base conversions without the need for donor DNA or double-strand breaks.
Read Less...
The expert speaker will provide a comprehensive overview of the current state of research in these areas, highlighting recent breakthroughs and discussing the potential of these technologies to transform genetic research and medicine. Attendees will gain insights into the latest advancements in the field, including the development of more efficient and versatile editors, improvements in delivery methods and efforts to reduce off-target effects.
Moreover, the webinar will explore the future applications of BE and PE, with a focus on their potential to address unmet medical needs. From correcting genetic mutations responsible for hereditary diseases to developing more effective cancer therapies, the possibilities are vast. The discussion will also touch on the ethical considerations and challenges associated with the clinical translation of these technologies, as well as the regulatory landscape that will shape their future use.
Join this webinar to explore the future of CRISPR and gene editing and discover how base and prime editing are poised to revolutionize the field of genetics.
Speaker
Dr. Jiabao Lv, PhD, Senior Protein Scientist, GenScript
Dr. Jiabao Lv is a dedicated Senior Protein Scientist at GenScript, where she has been actively involved in the research and development of Base Editors (BE) and Prime Editors (PE) over the past two years. She earned her PhD in Biochemistry and Molecular Biology from Jilin University in 2022 and gained additional research experience as a visiting PhD student at Aarhus University.
Dr. Lv’s work at GenScript focuses on developing enzyme product and activity assay, with a particular emphasis on CRISPR/Cas nucleases and molecular enzymes. In addition to her work at GenScript, Dr. Lv has developed a solid foundation in enzyme activity assays, crucial for advancing molecular biology.
She has authored five SCI papers in respected journals, covering areas such as enzyme immobilization, semi-rational enzyme design and the biosynthesis of prebiotics. Her research reflects a thoughtful and methodical approach to protein science, contributing to meaningful advancements in the field.
Message PresenterWho Should Attend?
This webinar is meant for academic and industry professionals in biotechnology and biopharmaceutical organizations involved in Gene and Cell Therapy development, as well as the following:
- Researchers interested in the latest advancements in gene editing technologies and their applications
- R&D scientists seeking to integrate CRISPR-based technologies into their projects and workflows
- Professionals involved in translational research and clinical trials related to ex vivo gene editing
What You Will Learn
Attendees will learn about:
- The mechanisms behind BE and PE technologies
- The latest research advancements and breakthroughs in CRISPR-based gene editing
- Potential therapeutic applications and the future impact of these technologies in medicine
Xtalks Partner
GenScript
GenScript is the leading contract research organization in the world providing gene, peptide, protein, CRISPR, and antibody. Since its foundation in 2002, GenScript has grown exponentially through partnerships with scientists conducting fundamental life science research, translational biomedical research, and early stage pharmaceutical development. The company is recognized as having built a best-in-class capacity and capability for biological research services, encompassing gene synthesis, peptide synthesis, custom antibody and protein engineering, and in vitro and in vivo pharmacology – all with the goal to Make Research Easy.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account